Drugs, bugs, and personalized medicine: Pharmacometabonomics enters the ring

The development of personalized treatment regimens, optimized to the measured biological status of the patient, to maximize benefits and minimize adverse effects, represents a major goal for 21st-century medicine (1). It is axiomatic that not all individuals respond to drug treatment in the same way, with lack of efficacy and adverse drug reactions (particularly idiosyncratic toxicity) representing a major cause of concern for both clinicians and the pharmaceutical industry.

[1]  A. Duncan,et al.  Soy consumption alters endogenous estrogen metabolism in postmenopausal women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  H. Adlercreutz,et al.  Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[4]  J. Lindenbaum,et al.  Interethnic variation in the metabolic inactivation of digoxin by the gut flora. , 1988, Gastroenterology.

[5]  C. Svanborg,et al.  Intestinal Colonization with Enterobacteriaceae in Pakistani and Swedish Hospital‐Delivered Infants , 1991, Acta paediatrica Scandinavica.

[6]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[7]  D. Nebert,et al.  Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[8]  I. Wilson,et al.  Induction of 5-oxoprolinuria in the rat following chronic feeding with N-acetyl 4-aminophenol (paracetamol). , 1993, Biochemical pharmacology.

[9]  I. Wilson,et al.  The role of gut microbiota in drug response. , 2009, Current pharmaceutical design.

[10]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[11]  I. Wilson,et al.  Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS‐DA , 2002, FEBS letters.

[12]  V. Mathan,et al.  Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. , 1989, Gut.

[13]  B. Drasar,et al.  Diet and faecal flora in three dietary groups in rural northern Nigeria , 1986, Journal of Hygiene.

[14]  V. P. Butler,et al.  Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. , 1981, The New England journal of medicine.

[15]  Ian D. Wilson,et al.  Metabolic Phenotyping in Health and Disease , 2008, Cell.

[16]  M. McCarthy,et al.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice , 2006, Proceedings of the National Academy of Sciences.

[17]  D. Bessesen,et al.  Human gut microbes associated with obesity , 2007 .

[18]  John C Lindon,et al.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism , 2009, Proceedings of the National Academy of Sciences.

[19]  Jeremy K. Nicholson,et al.  Gut microbiota: a potential new territory for drug targeting , 2008, Nature Reviews Drug Discovery.